{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:43:55Z","timestamp":1793947435651,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary or acquired resistant mechanisms prevent\u00a0the employment of individualized therapy with target drugs like the mTOR inhibitor everolimus (EVE) in hepatocellular carcinoma (HCC). The current study evaluated the effect of 1,25(OH)<jats:sub>2<\/jats:sub>Vitamin D (VitD) treatment on EVE sensitivity in established models of HCC cell lines resistant to everolimus (EveR). DNA content and colony formation assays, which measure the proliferative index, revealed that VitD pre-treatment re-sensitizes EveR cells to EVE treatment. The evaluation of epithelial and mesenchymal markers by western blot and immunofluorescence showed that VitD restored an epithelial phenotype in EveR cells, in which prolonged EVE treatment induced transition to mesenchymal phenotype. Moreover, VitD treatment prompted hepatic miRNAs regulation, evaluated by liver miRNA finder qPCR array. In particular, miR-375 expression was up-regulated by VitD in EveR cells, in which miR-375 was down-regulated compared to parental cells, with consequent inhibition of oncogenes involved in drug resistance and epithelial-mesenchymal transition (EMT) such as MTDH, YAP-1 and c-MYC. In conclusion, the results of the current study demonstrated that VitD can re-sensitize HCC cells resistant to EVE treatment triggering miR-375 up-regulation and consequently down-regulating several oncogenes responsible of EMT and drug resistance.<\/jats:p>","DOI":"10.1038\/s41598-019-48081-9","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T10:03:15Z","timestamp":1565604195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375\/oncogenes circuit"],"prefix":"10.1038","volume":"9","author":[{"given":"Donatella Paola","family":"Provvisiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Negri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Patalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simeoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortuna","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Ferrigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Simona","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"48081_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver. Electronic address, e. e. e. & European Association for the Study of the, L.","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address, e. e. e. & European Association for the Study of the, L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of hepatology 69, 406\u2013460, https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024 (2018).","journal-title":"Journal of hepatology"},{"key":"48081_CR2","unstructured":"GlobalCancerObservatory. Cancer today, http:\/\/gco.iarc.fr\/today\/home (2018)."},{"key":"48081_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/jnci\/dji315","volume":"97","author":"W Yeo","year":"2005","unstructured":"Yeo, W. et al. A randomized phase III study of doxorubicin versus cisplatin\/interferon alpha-2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. Journal of the National Cancer Institute 97, 1532\u20131538, https:\/\/doi.org\/10.1093\/jnci\/dji315 (2005).","journal-title":"Journal of the National Cancer Institute"},{"key":"48081_CR4","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2006.08.4046","volume":"25","author":"RG Gish","year":"2007","unstructured":"Gish, R. G. et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25, 3069\u20133075, https:\/\/doi.org\/10.1200\/JCO.2006.08.4046 (2007).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"48081_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12328-016-0670-7","volume":"9","author":"M Moriguchi","year":"2016","unstructured":"Moriguchi, M., Umemura, A. & Itoh, Y. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clinical journal of gastroenterology 9, 184\u2013190, https:\/\/doi.org\/10.1007\/s12328-016-0670-7 (2016).","journal-title":"Clinical journal of gastroenterology"},{"key":"48081_CR6","doi-asserted-by":"publisher","first-page":"9718","DOI":"10.18632\/oncotarget.6836","volume":"7","author":"C Pivonello","year":"2016","unstructured":"Pivonello, C. et al. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget 7, 9718\u20139731, https:\/\/doi.org\/10.18632\/oncotarget.6836\u00a0(2016).","journal-title":"Oncotarget"},{"key":"48081_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrclinonc.2014.136","volume":"11","author":"JM Llovet","year":"2014","unstructured":"Llovet, J. M. Liver cancer: time to evolve trial design after everolimus failure. Nature reviews. Clinical oncology 11, 506\u2013507, https:\/\/doi.org\/10.1038\/nrclinonc.2014.136 (2014).","journal-title":"Nature reviews. Clinical oncology"},{"issue":"7","key":"48081_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/molecules21070965","volume":"21","author":"Bowen Du","year":"2016","unstructured":"Du, B. & Shim, J. S. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules 21, https:\/\/doi.org\/10.3390\/molecules21070965 (2016).","journal-title":"Molecules"},{"key":"48081_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/carcin\/bgs140","volume":"33","author":"MV Iorio","year":"2012","unstructured":"Iorio, M. V. & Croce, C. M. microRNA involvement in human cancer. Carcinogenesis 33, 1126\u20131133, https:\/\/doi.org\/10.1093\/carcin\/bgs140 (2012).","journal-title":"Carcinogenesis"},{"key":"48081_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/cgt.2010.18","volume":"17","author":"J Ma","year":"2010","unstructured":"Ma, J., Dong, C. & Ji, C. MicroRNA and drug resistance. Cancer gene therapy 17, 523\u2013531, https:\/\/doi.org\/10.1038\/cgt.2010.18 (2010).","journal-title":"Cancer gene therapy"},{"key":"48081_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/hep.26369","volume":"58","author":"H Xia","year":"2013","unstructured":"Xia, H., Ooi, L. L. & Hui, K. M. MicroRNA-216a\/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 58, 629\u2013641, https:\/\/doi.org\/10.1002\/hep.26369 (2013).","journal-title":"Hepatology"},{"key":"48081_CR12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.bbrc.2012.07.127","volume":"425","author":"N Xu","year":"2012","unstructured":"Xu, N. et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochemical and biophysical research communications 425, 468\u2013472, https:\/\/doi.org\/10.1016\/j.bbrc.2012.07.127 (2012).","journal-title":"Biochemical and biophysical research communications"},{"key":"48081_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.gene.2013.12.043","volume":"538","author":"J Qin","year":"2014","unstructured":"Qin, J., Luo, M., Qian, H. & Chen, W. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene 538, 342\u2013347, https:\/\/doi.org\/10.1016\/j.gene.2013.12.043 (2014).","journal-title":"Gene"},{"key":"48081_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3892\/or.2014.3292","volume":"32","author":"N Tian","year":"2014","unstructured":"Tian, N., Han, Z., Li, Z., Zhou, M. & Fan, C. Lin28\/let-7\/Bcl-xL pathway: the underlying mechanism of drug resistance in Hep3B cells. Oncology reports 32, 1050\u20131056, https:\/\/doi.org\/10.3892\/or.2014.3292 (2014).","journal-title":"Oncology reports"},{"key":"48081_CR15","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/sj.bjc.6605958","volume":"103","author":"Y Tomimaru","year":"2010","unstructured":"Tomimaru, Y. et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha\/5-fluorouracil in hepatocellular carcinoma cells. British journal of cancer 103, 1617\u20131626, https:\/\/doi.org\/10.1038\/sj.bjc.6605958 (2010).","journal-title":"British journal of cancer"},{"key":"48081_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s10495-008-0256-z","volume":"13","author":"WP Tsang","year":"2008","unstructured":"Tsang, W. P. & Kwok, T. T. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis: an international journal on programmed cell death 13, 1215\u20131222, https:\/\/doi.org\/10.1007\/s10495-008-0256-z (2008).","journal-title":"Apoptosis: an international journal on programmed cell death"},{"key":"48081_CR17","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3892\/ijo.2014.2577","volume":"45","author":"K Liu","year":"2014","unstructured":"Liu, K. et al. miR222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. International journal of oncology 45, 1537\u20131546, https:\/\/doi.org\/10.3892\/ijo.2014.2577 (2014).","journal-title":"International journal of oncology"},{"key":"48081_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/jgs.12213","volume":"61","author":"RH Lee","year":"2013","unstructured":"Lee, R. H., Weber, T. & Colon-Emeric, C. Comparison of Cost-Effectiveness of Vitamin D Screening with That of Universal Supplementation in Preventing Falls in Community-Dwelling Older Adults. J Am Geriatr Soc 61, 707\u2013714, https:\/\/doi.org\/10.1111\/jgs.12213 (2013).","journal-title":"J Am Geriatr Soc"},{"key":"48081_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/eurpub\/cku119","volume":"25","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann, M. et al. Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. Eur J Public Health 25, 20\u201325, https:\/\/doi.org\/10.1093\/eurpub\/cku119 (2015).","journal-title":"Eur J Public Health"},{"key":"48081_CR20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s00198-014-2698-1","volume":"25","author":"K Zarca","year":"2014","unstructured":"Zarca, K. et al. Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture. Osteoporosis Int 25, 1797\u20131806, https:\/\/doi.org\/10.1007\/s00198-014-2698-1 (2014).","journal-title":"Osteoporosis Int"},{"key":"48081_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40618-014-0109-2","volume":"37","author":"CD Poole","year":"2014","unstructured":"Poole, C. D., Smith, J. C. & Davies, J. S. The short-term impact of vitamin D-based hip fracture prevention in older adults in the United Kingdom. J Endocrinol Invest 37, 811\u2013817, https:\/\/doi.org\/10.1007\/s40618-014-0109-2 (2014).","journal-title":"J Endocrinol Invest"},{"key":"48081_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00204-016-1804-x","volume":"91","author":"G Muscogiuri","year":"2017","unstructured":"Muscogiuri, G. et al. Vitamin D and chronic diseases: the current state of the art. Archives of toxicology 91, 97\u2013107, https:\/\/doi.org\/10.1007\/s00204-016-1804-x (2017).","journal-title":"Archives of toxicology"},{"key":"48081_CR23","first-page":"468","volume":"47","author":"S Miyaguchi","year":"2000","unstructured":"Miyaguchi, S. & Watanabe, T. The role of vitamin D3 receptor mRNA in the proliferation of hepatocellular carcinoma. Hepato-gastroenterology 47, 468\u2013472 (2000).","journal-title":"Hepato-gastroenterology"},{"key":"48081_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1478-3231.2007.01487.x","volume":"27","author":"FS Wu","year":"2007","unstructured":"Wu, F. S. et al. Calcitriol inhibits the growth of MHCC97 heptocellular cell lines by down-modulating c-met and ERK expressions. Liver international: official journal of the International Association for the Study of the Liver 27, 700\u2013707, https:\/\/doi.org\/10.1111\/j.1478-3231.2007.01487.x (2007).","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"48081_CR25","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.2174\/09298673113209990248","volume":"20","author":"J Guo","year":"2013","unstructured":"Guo, J. et al. 1, 25(OH)(2)D-3 Inhibits Hepatocellular Carcinoma Development Through Reducing Secretion of Inflammatory Cytokines from Immunocytes. Curr Med Chem 20, 4131\u20134141 (2013).","journal-title":"Curr Med Chem"},{"key":"48081_CR26","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.4161\/cc.10.12.15620","volume":"10","author":"TS Lisse","year":"2011","unstructured":"Lisse, T. S. & Hewison, M. Vitamin D: a new player in the world of mTOR signaling. Cell cycle 10, 1888\u20131889, https:\/\/doi.org\/10.4161\/cc.10.12.15620 (2011).","journal-title":"Cell cycle"},{"key":"48081_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1074\/jbc.M112.395947","volume":"288","author":"HJ Ting","year":"2013","unstructured":"Ting, H. J., Messing, J., Yasmin-Karim, S. & Lee, Y. F. Identification of microRNA-98 as a Therapeutic Target Inhibiting Prostate Cancer Growth and a Biomarker Induced by Vitamin D. J Biol Chem 288, 1\u20139, https:\/\/doi.org\/10.1074\/jbc.M112.395947 (2013).","journal-title":"J Biol Chem"},{"key":"48081_CR28","doi-asserted-by":"publisher","first-page":"41297","DOI":"10.1074\/jbc.M112.407189","volume":"287","author":"R Kasiappan","year":"2012","unstructured":"Kasiappan, R. et al. 1,25-Dihydroxyvitamin D3 Suppresses Telomerase Expression and Human Cancer Growth through MicroRNA-498. J Biol Chem 287, 41297\u201341309, https:\/\/doi.org\/10.1074\/jbc.M112.407189 (2012).","journal-title":"J Biol Chem"},{"key":"48081_CR29","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1093\/hmg\/dds031","volume":"21","author":"S Alvarez-Diaz","year":"2012","unstructured":"Alvarez-Diaz, S. et al. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet 21, 2157\u20132165, https:\/\/doi.org\/10.1093\/hmg\/dds031 (2012).","journal-title":"Hum Mol Genet"},{"key":"48081_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/B978-0-12-401676-7.00005-X","volume":"120","author":"X Meng","year":"2013","unstructured":"Meng, X., Thiel, K. W. & Leslie, K. K. Drug resistance mediated by AEG-1\/MTDH\/LYRIC. Advances in cancer research 120, 135\u2013157, https:\/\/doi.org\/10.1016\/B978-0-12-401676-7.00005-X (2013).","journal-title":"Advances in cancer research"},{"key":"48081_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ng.3228","volume":"47","author":"A Keren-Paz","year":"2015","unstructured":"Keren-Paz, A., Emmanuel, R. & Samuels, Y. YAP and the drug resistance highway. Nature genetics 47, 193\u2013194, https:\/\/doi.org\/10.1038\/ng.3228 (2015).","journal-title":"Nature genetics"},{"key":"48081_CR32","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/blood-2014-04-566711","volume":"123","author":"C Fauriat","year":"2014","unstructured":"Fauriat, C. & Olive, D. AML drug resistance: c-Myc comes into play. Blood 123, 3528\u20133530, https:\/\/doi.org\/10.1182\/blood-2014-04-566711 (2014).","journal-title":"Blood"},{"key":"48081_CR33","first-page":"1963","volume":"16","author":"RCAM anWaardenburg","year":"1996","unstructured":"anWaardenburg, R. C. A. M. et al. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res 16, 1963\u20131970 (1996). v.","journal-title":"Anticancer Res"},{"issue":"8","key":"48081_CR34","doi-asserted-by":"publisher","first-page":"e105381","DOI":"10.1371\/journal.pone.0105381","volume":"9","author":"Xiao-Na Pan","year":"2014","unstructured":"Pan, X. N. et al. Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation. Plos One 9, https:\/\/doi.org\/10.1371\/journal.pone.0105381 (2014).","journal-title":"PLoS ONE"},{"key":"48081_CR35","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1158\/0008-5472.Can-14-2743","volume":"75","author":"AJ Shen","year":"2015","unstructured":"Shen, A. J. et al. c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. Cancer Res 75, 4548\u20134559, https:\/\/doi.org\/10.1158\/0008-5472.Can-14-2743 (2015).","journal-title":"Cancer Res"},{"issue":"1","key":"48081_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-015-0326-0","volume":"14","author":"Yi Zhang","year":"2015","unstructured":"Zhang, Y. et al. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Mol Cancer 14, https:\/\/doi.org\/10.1186\/s12943-015-0326-0 (2015).","journal-title":"Molecular Cancer"},{"key":"48081_CR37","doi-asserted-by":"publisher","unstructured":"Kumar, K. et al. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep-Uk 5, https:\/\/doi.org\/10.1038\/srep09489 (2015).","DOI":"10.1038\/srep09489"},{"key":"48081_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000343839","volume":"1","author":"RS Finn","year":"2012","unstructured":"Finn, R. S. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver cancer 1, 247\u2013256, https:\/\/doi.org\/10.1159\/000343839 (2012).","journal-title":"Liver cancer"},{"key":"48081_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2014.7189","volume":"312","author":"AX Zhu","year":"2014","unstructured":"Zhu, A. X. et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. Jama 312, 57\u201367, https:\/\/doi.org\/10.1001\/jama.2014.7189 (2014).","journal-title":"Jama"},{"key":"48081_CR40","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jsbmb.2017.11.003","volume":"175","author":"NY Sofi","year":"2018","unstructured":"Sofi, N. Y. et al. Reproductive factors, nutritional status and serum 25(OH)D levels in women with breast cancer: A case control study. The Journal of steroid biochemistry and molecular biology 175, 200\u2013204, https:\/\/doi.org\/10.1016\/j.jsbmb.2017.11.003 (2018).","journal-title":"The Journal of steroid biochemistry and molecular biology"},{"issue":"2","key":"48081_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/ijerph14020127","volume":"14","author":"Cem Ekmekcioglu","year":"2017","unstructured":"Ekmekcioglu, C., Haluza, D. & Kundi, M. 25-Hydroxyvitamin D Status and Risk for Colorectal Cancer and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Epidemiological Studies. International journal of environmental research and public health 14, https:\/\/doi.org\/10.3390\/ijerph14020127 (2017).","journal-title":"International Journal of Environmental Research and Public Health"},{"key":"48081_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fonc.2014.00040","volume":"4","author":"M McDermott","year":"2014","unstructured":"McDermott, M. et al. In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Front Oncol 4, 40, https:\/\/doi.org\/10.3389\/fonc.2014.00040 (2014).","journal-title":"Front Oncol"},{"key":"48081_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bjc.2016.25","volume":"114","author":"T Vandamme","year":"2016","unstructured":"Vandamme, T. et al. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. British journal of cancer 114, 650\u2013658, https:\/\/doi.org\/10.1038\/bjc.2016.25 (2016).","journal-title":"British journal of cancer"},{"key":"48081_CR44","doi-asserted-by":"publisher","first-page":"6213872","DOI":"10.1155\/2016\/6213872","volume":"2016","author":"MJ Larriba","year":"2016","unstructured":"Larriba, M. J., Garcia de Herreros, A. & Munoz, A. Vitamin D and the Epithelial to Mesenchymal Transition. Stem cells international 2016, 6213872, https:\/\/doi.org\/10.1155\/2016\/6213872 (2016).","journal-title":"Stem cells international"},{"key":"48081_CR45","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nsmb.2296","volume":"19","author":"MR Fabian","year":"2012","unstructured":"Fabian, M. R. & Sonenberg, N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nature structural & molecular biology 19, 586\u2013593, https:\/\/doi.org\/10.1038\/nsmb.2296 (2012).","journal-title":"Nature structural & molecular biology"},{"key":"48081_CR46","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1101\/gr.089367.108","volume":"19","author":"I Lee","year":"2009","unstructured":"Lee, I. et al. New class of microRNA targets containing simultaneous 5\u2032-UTR and 3\u2032-UTR interaction sites. Genome research 19, 1175\u20131183, https:\/\/doi.org\/10.1101\/gr.089367.108 (2009).","journal-title":"Genome research"},{"key":"48081_CR47","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1101\/gr.139758.112","volume":"23","author":"J Hausser","year":"2013","unstructured":"Hausser, J., Syed, A. P., Bilen, B. & Zavolan, M. Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome research 23, 604\u2013615, https:\/\/doi.org\/10.1101\/gr.139758.112 (2013).","journal-title":"Genome research"},{"key":"48081_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcdb.2004.11.006","volume":"16","author":"BM Pickering","year":"2005","unstructured":"Pickering, B. M. & Willis, A. E. The implications of structured 5\u2032 untranslated regions on translation and disease. Seminars in cell & developmental biology 16, 39\u201347, https:\/\/doi.org\/10.1016\/j.semcdb.2004.11.006 (2005).","journal-title":"Seminars in cell & developmental biology"},{"key":"48081_CR49","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00438-017-1301-9","volume":"292","author":"K Zeljic","year":"2017","unstructured":"Zeljic, K., Supic, G. & Magic, Z. New insights into vitamin D anticancer properties: focus on miRNA modulation. Molecular genetics and genomics: MGG 292, 511\u2013524, https:\/\/doi.org\/10.1007\/s00438-017-1301-9 (2017).","journal-title":"Molecular genetics and genomics: MGG"},{"key":"48081_CR50","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/j.febslet.2011.06.025","volume":"585","author":"J Mazar","year":"2011","unstructured":"Mazar, J., DeBlasio, D., Govindarajan, S. S., Zhang, S. & Perera, R. J. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS letters 585, 2467\u20132476, https:\/\/doi.org\/10.1016\/j.febslet.2011.06.025 (2011).","journal-title":"FEBS letters"},{"key":"48081_CR51","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-09-2777","volume":"70","author":"Y Tsukamoto","year":"2010","unstructured":"Tsukamoto, Y. et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70, 2339\u20132349, https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2777 (2010).","journal-title":"Cancer Res"},{"key":"48081_CR52","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/ijc.28563","volume":"135","author":"JW Yan","year":"2014","unstructured":"Yan, J. W., Lin, J. S. & He, X. X. The emerging role of miR-375 in cancer. International journal of cancer 135, 1011\u20131018, https:\/\/doi.org\/10.1002\/ijc.28563 (2014).","journal-title":"International journal of cancer"},{"key":"48081_CR53","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/hep.22256","volume":"47","author":"Y Ladeiro","year":"2008","unstructured":"Ladeiro, Y. et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene\/tumor suppressor gene mutations. Hepatology 47, 1955\u20131963, https:\/\/doi.org\/10.1002\/hep.22256 (2008).","journal-title":"Hepatology"},{"key":"48081_CR54","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/onc.2012.128","volume":"32","author":"A Ward","year":"2013","unstructured":"Ward, A. et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 32, 1173\u20131182, https:\/\/doi.org\/10.1038\/onc.2012.128 (2013).","journal-title":"Oncogene"},{"key":"48081_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/onc.2016.185","volume":"36","author":"LA Selth","year":"2017","unstructured":"Selth, L. A. et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene 36, 24\u201334, https:\/\/doi.org\/10.1038\/onc.2016.185 (2017).","journal-title":"Oncogene"},{"key":"48081_CR56","first-page":"1561","volume":"9","author":"R He","year":"2017","unstructured":"He, R. et al. The essential role of MTDH in the progression of HCC: a study with immunohistochemistry, TCGA, meta-analysis and in vitro investigation. American journal of translational research 9, 1561\u20131579 (2017).","journal-title":"American journal of translational research"},{"key":"48081_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3431-1","volume":"17","author":"K Lee","year":"2017","unstructured":"Lee, K. et al. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas. BMC cancer 17, 441, https:\/\/doi.org\/10.1186\/s12885-017-3431-1 (2017).","journal-title":"BMC cancer"},{"key":"48081_CR58","doi-asserted-by":"publisher","first-page":"e45119","DOI":"10.1371\/journal.pone.0045119","volume":"7","author":"KY Jang","year":"2012","unstructured":"Jang, K. Y. et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. Plos One 7, e45119, https:\/\/doi.org\/10.1371\/journal.pone.0045119 (2012).","journal-title":"Plos One"},{"key":"48081_CR59","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.2147\/OTT.S104556","volume":"9","author":"Z Wang","year":"2016","unstructured":"Wang, Z. et al. Metadherin regulates epithelial-mesenchymal transition in carcinoma. OncoTargets and therapy 9, 2429\u20132436, https:\/\/doi.org\/10.2147\/OTT.S104556 (2016).","journal-title":"OncoTargets and therapy"},{"key":"48081_CR60","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.yexcr.2016.11.024","volume":"350","author":"HH Ling","year":"2017","unstructured":"Ling, H. H., Kuo, C. C., Lin, B. X., Huang, Y. H. & Lin, C. W. Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer. Experimental cell research 350, 218\u2013225, https:\/\/doi.org\/10.1016\/j.yexcr.2016.11.024 (2017).","journal-title":"Experimental cell research"},{"key":"48081_CR61","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1002\/jcp.25797","volume":"232","author":"T Chen","year":"2017","unstructured":"Chen, T., You, Y., Jiang, H. & Wang, Z. Z. Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. Journal of cellular physiology 232, 3261\u20133272, https:\/\/doi.org\/10.1002\/jcp.25797 (2017).","journal-title":"Journal of cellular physiology"},{"key":"48081_CR62","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.exphem.2010.03.020","volume":"38","author":"J Yang","year":"2010","unstructured":"Yang, J. et al. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo. Experimental hematology 38, 666\u2013676, https:\/\/doi.org\/10.1016\/j.exphem.2010.03.020 (2010).","journal-title":"Experimental hematology"},{"key":"48081_CR63","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell, A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26, 1588\u20131595, https:\/\/doi.org\/10.1200\/JCO.2007.14.0988 (2008).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"48081_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0277-5379(90)90254-Q","volume":"26","author":"LJ Hofland","year":"1990","unstructured":"Hofland, L. J., van Koetsveld, P. M. & Lamberts, S. W. Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. European journal of cancer 26, 37\u201344 (1990).","journal-title":"European journal of cancer"},{"key":"48081_CR65","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s12020-016-1079-2","volume":"56","author":"C Pivonello","year":"2017","unstructured":"Pivonello, C. et al. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. Endocrine 56, 603\u2013620, https:\/\/doi.org\/10.1007\/s12020-016-1079-2 (2017).","journal-title":"Endocrine"},{"key":"48081_CR66","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nature protocols 1, 2315\u20132319, https:\/\/doi.org\/10.1038\/nprot.2006.339 (2006).","journal-title":"Nature protocols"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48081-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48081-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48081-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:34:34Z","timestamp":1671280474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48081-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48081"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48081-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11695"}}